Alzamend Neuro (ALZN) Stock Overview
A clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ALZN Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Top Community Narratives
Alzamend Neuro, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.16 |
| 52 Week High | US$3.60 |
| 52 Week Low | US$0.84 |
| Beta | 0.14 |
| 1 Month Change | 4.50% |
| 3 Month Change | 25.19% |
| 1 Year Change | -59.72% |
| 3 Year Change | -99.83% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Alzamend Neuro's Novel Lithium Formulation Will Target Major Mental Health Challenges
Catalysts AL001 : a novel lithium formulation targeting Alzheimer's disease, Bipolar Disorder, Major Depressive Disorder (MDD), and PTSD. Phase II studies show promising safety/efficacy, with trials ongoing as of 2025.Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Alzamend Neuro (NASDAQ:ALZN) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...We're Not Very Worried About Alzamend Neuro's (NASDAQ:ALZN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Alzamend stock falls amid start of AL001 dosing in healthy people in Alzheimer's trial
Alzamend Neuro (NASDAQ:ALZN) said it began dosing healthy people in a phase 2A study of oral drug AL001 treat people with dementia related to Alzheimer’s. The placebo-controlled trial (AL001-02) started in May to evaluate the safety and tolerability of AL001 under multiple-dose setting, to determine the maximum tolerated dose, the company said in an Oct. 5 press release. Based on a recommendation by the U.S. Food and Drug Administration (FDA) after its review on Alzamend's pre-investigational new drug briefing package to develop AL001 for bipolar, major depressive and post-traumatic stress disorders, the ongoing clinical trial in Alzheimer's patients was expanded, the company added. ALZN -6.52% to $1.29 premarket Oct. 5Alzamend seeks FDA nod for early-stage trial of its therapy for Alzheimer’s type dementia
Clinical-stage biopharma Alzamend Neuro (NASDAQ:ALZN) on Thursday said it had submitted an investigational new drug (IND) application to the U.S. FDA for a phase 1/2A trial of its immunotherapy product candidate ALZN002 for the treatment of dementia of the Alzheimer's type. ALZN said the product candidate consists of dendritic cells, or activated white blood cells taken from an individual patients so that they can be engineered outside of the body to attack Alzheimer's-related amyloid-beta proteins. The purpose of the phase 1/2A trial would be to assess the safety, tolerability, and efficacy of multiple ascending doses of ALZN002 compared to placebo in 20‑30 subjects with mild to moderate dementia of the Alzheimer’s type, ALZN said in a statement. ALZN stock -1.7% to $1.16 in premarket trading. Shares of ALZN gained 6.3% on Wednesday, amidst a broader rally in drug companies that are working on Alzheimer's treatments sparked by positive data from Biogen (BIIB) and Eisai (OTCPK:ESALY).Alzamend Neuro receives positive pre-IND response from FDA for AL001
Alzamend Neuro (NASDAQ:ALZN) said on Monday it had received a written response to its meeting request relating to its Type B Pre-Investigational New Drug application from the U.S. Food and Drug Administration. The company said the FDA’s response provides a path for its planned clinical development of AL001 for the treatment of bipolar disorder, major depressive disorder and post-traumatic stress disorder. AL001 has the potential to deliver benefits of marketed lithium carbonate while avoiding current toxicities associated with lithium. Alzamend expects to file INDs for bipolar disorder, MDD and PTSD upon the completion of the current Phase IIA multiple ascending dose study.Alzamend: Biotech To Watch With 2 Drugs Targeting Multi-Billion Dollar Alzheimer's Market
Alzamend reported positive results from its phase 1 study using AL001 for the treatment of patients with Alzheimer's Disease. The phase 2 multiple ascending dose study using AL001 treating this patient population is expected to begin Q2 of 2022. AL002 is another shot on goal targeting Alzheimer's Disease and it is a cell therapy focused on boosting T-cell activity in the body to clear amyloid from the brain. It is estimated that the global market opportunity for Alzheimer's Disease could reach $25.5 billion by 2025.Shareholder Returns
| ALZN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.6% |
| 1Y | -59.7% | 41.1% | 18.6% |
Return vs Industry: ALZN underperformed the US Biotechs industry which returned 41.1% over the past year.
Return vs Market: ALZN underperformed the US Market which returned 18.6% over the past year.
Price Volatility
| ALZN volatility | |
|---|---|
| ALZN Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 10.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ALZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALZN's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 5 | Stephan Jackman | www.alzamend.com |
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Alzamend Neuro, Inc. Fundamentals Summary
| ALZN fundamental statistics | |
|---|---|
| Market cap | US$4.41m |
| Earnings (TTM) | -US$7.54m |
| Revenue (TTM) | n/a |
Is ALZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALZN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.54m |
| Earnings | -US$7.54m |
Last Reported Earnings
Jan 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.98 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ALZN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 23:19 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alzamend Neuro, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |